Clinical Trial Update: A Dose Escalation and Cohort Expansion Study of NKTR-214 in Combination With Nivolumab and Other Anti-Cancer Therapies in Patients With Select Advanced Solid Tumors [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial evaluating NKTR-214 in combination with nivolumab and other anti-cancer therapies in select advanced solid tumors completed with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastric Cancer
• Hr Her2- Breast Cancer
• Melanoma
• Non-small Cell Lung Cancer
• Renal Cell Carcinoma
• Triple-negative Breast Cancer
• Urothelial Carcinoma

Drugs mentioned

• NKTR-214 (bempegaldesleukin)
• nivolumab (nivolumab)

Snippet

Sponsor: Nektar Therapeutics | Conditions: Melanoma, Renal Cell Carcinoma | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2023-03-13